Tempus AI, Inc. Common Stock (TEM.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS
Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 11 advisor reports and comparisons.
Updated on 12 April 2026Deep analysis 12 April 2026
Russlan Ramdowar
Gemini 3 ProSuperintelligence AI
The Anthropologist FrameworkModel rating
Buy
5-Year Return Est.
+282.9%
TEM.NASDAQ does not currently pay dividends
Historical prices and published forecast
- Observed price
- Published advisor forecast
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning
Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.
| Quarter | Forecast | Total return | Scenario |
|---|---|---|---|
| $40.8 | -5.0% | The brutal reality of the Warsh 'Sound Money' regime and the lingering shock of the Hormuz energy crisis continue to penalize growth equities. Hospital budget freezes limit near-term physical sequencing volume. | |
| $39.6 | -7.9% | Earnings reflect sluggish adoption at the clinical tier as inflation pressures persist. However, subtle strength in pharma data licensing begins to emerge under the surface, creating a floor. | |
| $42.7 | -0.5% | The Alpha Gap begins to close. The market realizes that Tempus's data licensing revenue is highly resilient to the macro shock. First signals of major pharma R&D pivots toward in-silico trials. | |
| $47.9 | +11.5% | A clear inflection point. Annual earnings show significant gross margin expansion as algorithm-as-a-service adoption displaces hardware costs. The 'AI capex reckoning' narrative detaches from applied bio-AI. | |
| $50.7 | +18.2% | Steady accumulation phase. The network topology advantage becomes obvious as smaller competitors face insolvency under high interest rates, leaving Tempus to consolidate market share. | |
| $54.3 | +26.4% | FDA provides clearer guidance on SaMD, specifically benefiting Tempus's retrospective data advantage. Institutional capital rotates back into biotech infrastructure. | |
| $61.9 | +44.1% | Explosive growth driven by multiple FDA approvals for predictive algorithms. The civilizational trajectory of AI healthcare integration reaches critical mass at the provider level. | |
| $66.8 | +55.7% | Compounding momentum continues as big pharma standardizes on Tempus databases for synthetic control arms. The thermodynamic efficiency of the business model is now undeniably proven. | |
| $70.2 | +63.4% | Mild consolidation after rapid gains. The broader market digests a plateau in macro interest rates, but Tempus holds ground due to non-cyclical biological demand. | |
| $76.5 | +78.1% | Expansion beyond oncology into cardiology and neurology begins to bear fruit, expanding the Total Addressable Market without requiring proportional capex. | |
| $88.0 | +104.9% | Scale dominance is fully achieved. The data moat is universally recognized as impenetrable. Speculation of Big Tech acquisition attempts drives a massive re-rating of the asset's intrinsic value. | |
| $96.8 | +125.4% | Network effects lock in remaining laggard hospital systems. Medicare establishes universal reimbursement codes for key Tempus AI diagnostics. | |
| $103 | +138.9% | Growth stabilizes at a high baseline. The company operates as a pure negentropy engine, converting patient data into high-margin recurring cash flows effortlessly. | |
| $111 | +158.0% | Launch of next-generation pan-disease predictive models solidifies Tempus as the fundamental operating system for advanced human healthcare. | |
| $124 | +188.9% | Global demographic realities (aging populations) force a massive structural reliance on AI diagnostics to offset shrinking human physician labor pools. | |
| $130 | +203.4% | Routine quarter. Revenue streams from data licensing act as a utility-like toll on the entire pharmaceutical industry. | |
| $139 | +224.6% | Advancements in targeted therapies require hyper-specific genomic matching, cementing Tempus's role at the point of care. | |
| $145 | +237.6% | Minor regulatory friction regarding data sharing protocols causes a slight deceleration in price momentum, but fundamentals remain pristine. | |
| $157 | +264.6% | Civilizational alignment reaches its zenith as precision medicine becomes the absolute baseline standard of care globally. Tempus dominates the US informational topology. | |
| $164 | +282.9% | Terminal maturity phase of the 5-year forecast. The asset has successfully navigated the macro chaos of 2026 to emerge as a structurally irreplaceable civilizational institution. |
1. Investment Thesis — Base Case
The True Price trajectory for Tempus AI reflects a painful but necessary transition from liquidity-driven bubble pricing to monopoly-driven cash flow realization. The market's current panic, driven by the broader generative AI capex reckoning and Warsh's hawkish monetary reset, has temporarily decoupled the stock from its deep biological utility. Homo sapiens are fundamentally survival-oriented; as the global population ages, precision oncology becomes a non-discretionary civilizational imperative. Tempus operates at the exact intersection of this biological mandate and the thermodynamic efficiency of applied AI. By aggregating the largest multimodal clinical and molecular dataset, it sits at an insurmountable network chokepoint. While the 2026 macro environment imposes high capital costs and hospital budget constraints, these frictions will eventually force pharmaceutical giants to rely entirely on Tempus's data to salvage their own collapsing R&D ROI. As the reflexivity cycle stabilizes, the Alpha Gap will close, driving sustained compounding growth through 2031.
- Pharma Budget Repurposing: Drugmakers offset DOGE-induced FDA delays by purchasing Tempus's real-world evidence data, accelerating recurring revenue streams.
- Margin Expansion via Software: The company transitions from hardware-heavy wet lab sequencing to near-zero marginal cost AI algorithmic testing.
- Moat Deepening: Accumulating longitudinal patient records creates a thermodynamic flywheel that smaller generic competitors cannot replicate.
- Valuation Normalization: The market stops pricing Tempus as discretionary SaaS and reprices it as critical, non-cyclical bio-infrastructure.
- Macro Digest: The asset eventually outgrows the 'Sound Money' valuation drag through sheer cash-flow generation by 2028.
2. Scenarios & Signals
2.1. Bull Case
If the biological anchoring proves even stronger than anticipated and the Big Tech acquisition opportunity materializes, Tempus becomes the foundational layer of global healthcare AI. In this scenario, the transition to software-only margins happens twice as fast, and FDA fast-tracks make Tempus's algorithms the default standard of care across multiple disease states beyond oncology.
- Big Tech Bidding War: Hyperscalers fighting over proprietary data acquire Tempus at a massive premium.
- Universal Reimbursability: Medicare universally covers Tempus algorithms, driving instant, zero-CAC revenue.
- Negentropy Dominance: The compute costs drop due to specialized silicon, driving free cash flow margins above 35%.
- Pan-disease Expansion: The platform seamlessly scales from cancer into cardiology and neurology.
2.2. Bear Case
If the Warsh monetary regime persists longer than expected and open-source medical models destroy the data moat, Tempus becomes a thermodynamic value trap. The cost of running massive AI models outstrips the revenue hospitals are willing to pay, and pharma companies build their own synthetic data architectures to bypass Tempus entirely.
- Sustained Cost of Capital Penalty: High rates prevent the company from funding necessary compute expansions without dilutive equity raises.
- Open-Source Disruption: Commoditized medical LLMs provide 90% of Tempus's utility for 10% of the cost.
- Hospital Insolvency: Widespread hospital bankruptcies freeze the adoption of new digital pathology tools.
- Legal Entropy: Genomic privacy laws fragment the database, destroying the core network effect.
2.3. Behavioral Alpha Signals
Sentiment, repricing cycle, crowd narrative, catalyst, and macro alignment.Expected Volatility Regime
Greed and Fear Index
Cycle Position
The reset is mostly complete and price drifts toward fair value.
What does Media Tell? (Crowd Consensus)
The noisy human crowd currently perceives Tempus as just another casualty of the late-2025 'AI Capex Reckoning.' Burned by generative AI vaporware and spooked by the Warsh 'Sound Money' interest rate shock, retail and institutional generalists have indiscriminately dumped unprofitable tech. The consensus narrative groups Tempus with discretionary SaaS, assuming that TrumpRx margin pressures and inflation will freeze pharma and hospital spending, permanently stalling the company's growth. The crowd is anchored to the 50% price crash, treating the asset as a broken IPO rather than a foundational biological infrastructure play.
What Crowds Get Wrong? (Alpha/Value Gap)
The variant perception lies in the crowd's inability to distinguish between the thermodynamic waste of generative AI chatbots and the deterministic biological utility of precision oncology. Tempus is not monetizing human attention; it is monetizing survival. The market fundamentally misprices Tempus's network topology: it has achieved an irreversible monopolistic chokepoint over US multimodal clinical data. Furthermore, the consensus believes pharma budget cuts hurt Tempus; the reality is that pharma *must* buy Tempus's real-world data precisely because traditional wet-lab R&D has become too expensive under new regulatory and pricing pressures. The crowd is pricing a software company; they should be pricing a civilizational negentropy engine.
When will Value Gap Repricing Happen? (Repricing Catalyst)
The alpha gap will close when Tempus reports consecutive quarters of expanding gross margins driven by data licensing and algorithm-as-a-service revenues, fully decoupled from their physical sequencing costs. This inflection point, likely occurring in late 2026 or early 2027, will unequivocally prove to the market that pharma is increasing, not cutting, its reliance on Tempus to navigate R&D budget compression.
How is Asset Influenced by Macro Regime?
The macro regime is highly antagonistic in the near term but structurally supportive in the long arc. The Warsh 'Sound Money' phase and Treasury liquidity stress brutally penalize long-duration assets reliant on capital markets. However, the exact same stagflationary pressures forcing this monetary regime are also forcing the healthcare sector to seek extreme automation. Tempus is shielded by the absolute inelasticity of biological disease; cancer does not care about the yield curve.
3. Positive & Negative Factors, Risks & Opportunities
3.1. Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Structural or operating forces that support this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Multimodal DATA Network MOAT | Competitive Positioning | +25% | Not quantified | In information theory, systems that aggregate and structure proprietary data at scale capture disproportionate civilizational value. Tempus sits at an insurmountable network chokepoint, ingesting multimodal data (genomic sequencing, clinical records, digital pathology) from thousands of academic medical centers and community oncologists. This is not open-source internet text that can be scraped by cheap LLMs; it is heavily siloed, privacy-protected human biological exhaust. As this dataset grows, the algorithmic accuracy compounds, drawing more physicians, which yields more data. This reflexivity creates a monopolistic topology that is mathematically prohibitive for late-arriving competitors to replicate. |
| Pharma R&d Efficiency Mandate | Operational Efficiency | +22% | Not quantified | The 2026 TrumpRx drug-pricing pressures and DOGE-induced FDA administrative bottlenecks are annihilating traditional pharmaceutical profit margins. To survive this thermodynamic drag, big pharma must drastically increase its R&D negentropy. Tempus provides the exact mechanism: in-silico trial design and synthetic control arms using its massive real-world evidence (RWE) databases. By forcing the broader healthcare ecosystem to become more efficient, the macro-political stress inadvertently herds capital directly into Tempus's high-margin data licensing business. Pharma companies can no longer afford to ignore algorithmic trial optimization, cementing Tempus as a non-negotiable vendor. |
| Inelastic Biological Demand | Sector And Industry | +18% | Not quantified | Within the Anthropologist framework, Tempus serves the deepest of biological imperatives: the avoidance of mortality. Humans will eagerly sacrifice discretionary consumption during the 2026 stagflationary shock, but they will liquidate all available resources to combat stage IV carcinoma. Tempus's precision oncology platform targets a fundamentally non-discretionary civilizational need. Unlike superficial generative AI applications that monetize dopamine loops, Tempus monetizes survival probability. As the global population ages and cancer incidence rises, this biological anchoring guarantees a persistent, structurally mandated revenue baseline that bends but absolutely does not break under macroeconomic stress, establishing a multi-decade compounding tailwind. |
| Algorithm AS A Service Margin Shift | Innovation And Product | +15% | Not quantified | Tempus is undergoing a profound thermodynamic phase transition. Initially burdened by the high capital expenditure and physical entropy of operating wet labs for physical genomic sequencing, the firm is aggressively pivoting toward deploying AI algorithms (like its ECG-based predictive models or digital pathology screens) directly onto existing hospital hardware. This shifts its revenue mix toward near-zero marginal cost software licensing. As algorithms displace physical reagents, Tempus becomes a pure negentropy engine, converting proprietary insights into extreme gross margin expansion, driving significant price appreciation as the market rerates its cash flow potential. |
Near-certain negative forces
Top Frictions / Headwinds
Expected frictions that can slow, cap, or damage this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Warsh Sound Money Squeeze | Macroeconomic And Macrofinancial | -15% | Not quantified | The transition to the Warsh 'Sound Money' regime and the resulting yield-curve steepener act as a brutal gravitational pull on long-duration equity valuations. Tempus, while exhibiting strong revenue growth, still requires vast capital to expand its compute infrastructure and acquire new clinical nodes. With the risk-free rate elevated and private banks absorbing Treasury runoff, the cost of capital for unprofitable or marginally profitable growth technology stocks is prohibitively high. This macrofinancial friction compresses valuation multiples, ensuring that even if Tempus executes perfectly on its biological mandate, its equity price faces relentless discounting drag. |
| Hospital System Solvency Crisis | Sector And Industry | -12% | Not quantified | The primary deployment nodes for Tempus's physical sequencing and algorithmic products are human hospital systems, which are currently suffering extreme thermodynamic inefficiency. Crushed by wage inflation, nursing shortages, and cuts to federal healthcare subsidies under the DOGE agenda, hospital operating margins are collapsing. While Tempus offers long-term efficiency, cash-strapped hospital administrators routinely freeze near-term IT and advanced diagnostic budgets to survive quarterly cash-flow crises. This localized capital starvation directly slows the velocity of Tempus's clinical rollout and delays the network saturation required for maximum algorithmic compounding. |
| Thermodynamic Compute COST | Operational Efficiency | -10% | Not quantified | Training and running inference on multimodal biological datasets (especially high-resolution digital pathology and whole-exome sequencing) is thermodynamically punishing. As the energy crisis sparked by the 2026 Hormuz closure spikes power costs and helium shortages threaten AI hardware supply chains, Tempus faces spiraling compute expenses. The firm is fighting physical entropy; the energy and silicon required to maintain its predictive edge scale non-linearly with data volume. This structural cost pressure severely limits near-term profitability and free cash flow generation, disappointing impatient market participants demanding immediate AI monetization. |
| Genomic Privacy Backlash | Regulatory | -8.0% | Not quantified | Homo sapiens exhibit irrational but politically potent attachments to their biological data. As Tempus scales its monetization of patient records, the probability of regulatory backlash regarding genomic data privacy and secondary licensing consent increases. State-level legislatures, responding to populist privacy narratives, are likely to introduce fragmented data-fencing laws that increase compliance costs. This legal entropy forces Tempus to expend capital on legal architecture rather than scientific innovation, marginally reducing the liquidity and fungibility of its core data asset over the five-year horizon. |
3.2. Risks & Opportunities
Plausible downside scenarios
Tail Risks
Less likely downside scenarios that could materially hurt the outcome if they occur.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| OPEN DATA Legislative Mandate | 15% | -55% | Driven by populist anti-monopoly sentiment and a push to democratize AI, the US government passes legislation mandating that all anonymized clinical and genomic data generated via federally funded systems (Medicare/Medicaid) must be deposited into an open-source public commons. This legislative strike directly attacks Tempus's information topology, evaporating its proprietary data moat overnight and reducing the firm to a low-margin software service provider competing purely on generic compute efficiency. |
| Catastrophic Algorithm Hallucination | 10% | -40% | A systemic flaw in a widely deployed Tempus diagnostic algorithm leads to a statistically significant cluster of misdiagnoses or incorrect therapeutic recommendations in oncology patients. The trigger is an undetected bias in the training data interacting with a novel cancer phenotype. This biological failure leads to immediate FDA suspension of the tool, massive liability litigation, and a permanent destruction of trust among oncologists, unwinding the network effect completely. |
Plausible upside scenarios
Tail Opportunities
Less likely upside scenarios that could materially improve the outcome if they occur.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| BIG TECH BIO Acquisition | 25% | +45% | A mega-cap technology incumbent (e.g., Microsoft, Alphabet), desperate to secure a proprietary moat in healthcare AI amid tightening sovereign data rules, bypasses organic growth and acquires Tempus outright at a massive premium. This is triggered if open-source models commoditize standard LLMs, forcing hyperscalers to buy physical-world data monopolies. Tempus's high information density and clinical network make it the ultimate biological integration layer for a tech giant's cloud ecosystem. |
| Universal MRD Standard Adoption | 30% | +35% | Tempus secures a blanket FDA approval and universal CMS reimbursement for an algorithmic Minimal Residual Disease (MRD) testing protocol that effectively replaces routine physical scans for post-treatment cancer monitoring. Triggered by a breakthrough in their multimodal predictive accuracy, this event transforms Tempus from a discretionary diagnostic tool into a mandated, recurring civilizational standard of care, unlocking tens of billions in highly predictable, high-margin annual recurring revenue. |
5. References & Context
Search behavior, retained evidence, supplied context, and response token details.This Thinker run did not use external web search. The model relied on the supplied research context and its internal reasoning.
Context supplied to the model
Public-safe inputs retained with this immutable forecast publication.
- 01
Market data
inmemory_base_placeholders__latest_eod_close_price_with_stats__var1
- 02
Global context in this run
Used
- 03
Fundamental data in this run
Not used
- 04
Subject context
Equity-specific subject and market context
- 05
Global context
Standard global market and cross-asset context
- 06
Task framework
Standard investment-forecast task guidelines
- 07
Advisor framework
Superintelligence The Anthropologist
- 08
Forecast output requested
Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-04-10
Download Archived SnapshotCoverage 2026-01-01 to 2026-04-10 · Knowledge cutoff 2026-04-10
- File size
- 73.5K bytes
- Words
- 9.8K words
- Characters
- 73.5K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-04-10.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
annual: 0 periods; quarterly: 0 periods
Currencies cited: USD (quote USD).
Original published forecast
Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.
A consensus thesis is not available for this publication.